ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,360.48
0.00%
Brent Oil
82.585
0.00%
Bitcoin
61,073.72
0.46%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ZyVersa Therapeutics Inc (ZVSA)

  7. ZyVersa Therapeutics Inc (ZVSA) News

ZyVersa Therapeutics (ZVSA)

ZyVersa Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZVSA
DateTimeSourceHeadlineSymbolCompany
29/04/202412:57GlobeNewswire Inc.ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s DiseaseNASDAQ:ZVSAZyVersa Therapeutics Inc
04/04/202412:57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesNASDAQ:ZVSAZyVersa Therapeutics Inc
25/03/202412:17GlobeNewswire Inc.ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
18/03/202411:57GlobeNewswire Inc.ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney DiseaseNASDAQ:ZVSAZyVersa Therapeutics Inc
14/03/202411:57GlobeNewswire Inc.ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024NASDAQ:ZVSAZyVersa Therapeutics Inc
08/03/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
08/03/202422:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
29/02/202412:57GlobeNewswire Inc.ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat ObesityNASDAQ:ZVSAZyVersa Therapeutics Inc
28/02/202412:57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its ComplicationsNASDAQ:ZVSAZyVersa Therapeutics Inc
22/02/202412:47GlobeNewswire Inc.ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic OptionNASDAQ:ZVSAZyVersa Therapeutics Inc
14/02/202421:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ZVSAZyVersa Therapeutics Inc
14/02/202412:53GlobeNewswire Inc.ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological DiseasesNASDAQ:ZVSAZyVersa Therapeutics Inc
07/02/202413:02GlobeNewswire Inc.ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key MilestonesNASDAQ:ZVSAZyVersa Therapeutics Inc
31/01/202412:57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 DiabetesNASDAQ:ZVSAZyVersa Therapeutics Inc
24/01/202412:57GlobeNewswire Inc.ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s DiseaseNASDAQ:ZVSAZyVersa Therapeutics Inc
19/01/202411:19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ZVSAZyVersa Therapeutics Inc
17/01/202412:52GlobeNewswire Inc.ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain MetastasisNASDAQ:ZVSAZyVersa Therapeutics Inc
10/01/202413:06GlobeNewswire Inc.ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All AccessNASDAQ:ZVSAZyVersa Therapeutics Inc
04/01/202412:50GlobeNewswire Inc.ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital MarketsNASDAQ:ZVSAZyVersa Therapeutics Inc
03/01/202413:07GlobeNewswire Inc.ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024NASDAQ:ZVSAZyVersa Therapeutics Inc
22/12/202321:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
18/12/202313:12GlobeNewswire Inc.ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”NASDAQ:ZVSAZyVersa Therapeutics Inc
14/12/202312:01GlobeNewswire Inc.ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200NASDAQ:ZVSAZyVersa Therapeutics Inc
11/12/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
08/12/202321:44Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ZVSAZyVersa Therapeutics Inc
07/12/202316:20GlobeNewswire Inc.ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 DiabetesNASDAQ:ZVSAZyVersa Therapeutics Inc
07/12/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
07/12/202302:00GlobeNewswire Inc.ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public OfferingNASDAQ:ZVSAZyVersa Therapeutics Inc
06/12/202312:20GlobeNewswire Inc.ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome PathwaysNASDAQ:ZVSAZyVersa Therapeutics Inc
30/11/202316:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVSA

Your Recent History

LSE
PET
Petrel Resources
LSE
TERN
Tern
LSE
VAST
Vast Resources
LSE
SCE
Surface Transforms
LSE
GKP
Gulf Keystone Petroleum
LSE
SCLP
Scancell
LSE
POS
Plexus
LSE
EEE
Empire Metals
LSE
OXB
Oxford Biomedica
LSE
ITV
Itv
LSE
AGL
Angle
LSE
PANR
Pantheon Resources
LSE
GOLD
LSE
SRSP
Sirius Petroleum
LSE
ENET
Ethernity Networks
LSE
AAZ
Anglo Asian Mining
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved